Cancer is one of the most prevalent fatal chronic disorders with a high mortality rate due to its invasive nature and prolonged duration of disease. According to American Cancer Society (ASC), around 22,240 women are expected to be diagnosed with ovarian cancer, and around 14,070 deaths are expected from the disease in 2018.
Furthermore, introduction of new drugs has propelled the poly adenosine diphosphate ribose polymerase market growth. For instance, the U.S. Food & Drug Administration approved 3 PARP inhibitors—Olaparib, Rucaparib, and Niraparib. These drugs are a potential alternative that aid in treatment of ovarian and other cancers after paclitaxel.
Moreover, combination of these PARP inhibitors with other therapies such as monoclonal antibodies is under research. For instance, in May 2018, TESARO, Inc.—an oncology-focused biopharmaceutical company— announced collaboration with Genentech—a member of the Roche Group—to evaluate the combination of the PD-L1 antibody— Atezolizumab (TECENTRIQ), the MEK inhibitor cobimetinib (COTELLIC), and TESARO’s PARP inhibitor ZEJULA (Niraparib) — in patients with platinum-sensitive ovarian cancer. In April 6, 2018, the U.S. Food and Drug Administration (FDA) approved Rubraca (rucaparib) tablets –manufactured by Clovis Oncology Inc.—for the treatment of recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in adult patients.
Get PDF for more Professional and Technical insights@
Poly Adenosine Diphosphate Ribose Polymerase Market Regional Insights
North America and Europe are expected to witness significant growth in the poly adenosine diphosphate ribose polymerase market over the forecast period. Increasing demand for approved drugs, owing to high prevalence of various types of cancer is expected to facilitate growth of the market, in the U.S. For instance, according to American Cancer Society (ASC), around 164,690 new cases are expected to be diagnosed with prostate cancer in 2018.
New product launches and robust pipeline of PARP inhibitors is expected to boost the North America, and Europe PARP inhibitors market growth over the forecast period. For instance, Clovis Oncology launched Rubraca (Rucaparib) in 2016, and Tesaro, Inc. launched Zejula (Niraparib) in 2017. Moreover, Lynparza (Olaparib) manufactured by AstraZeneca Plc was approved by the U.S. Food & Drug Administration for the treatment of germline BRCA-mutated (gBRCAm), human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer in January 2018.
About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.
Coherent Market Insights
1001 4th Ave,
Seattle, WA 98154